{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:40:13Z","timestamp":1792539613110,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Enavogliflozin, a sodium\u2010glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized, open\u2010label, two\u2010sequence, three\u2010period crossover study was conducted. Participants received one of the following three treatments for 6\u00a0days in each period: enavogliflozin 0.3\u00a0mg once daily (E), glimepiride 2\u00a0mg once daily and metformin 1000\u2009mg twice daily combination (GM) or the combination of all three study drugs (E\u2009+\u2009GM). Serial blood and urine samples were collected for PK and PD assessments at steady state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for the maximum plasma concentration (C\n                      <jats:sub>max,ss<\/jats:sub>\n                      ) of enavogliflozin, glimepiride and metformin were 1.0811 (1.0273\u20131.1378), 1.1495 (1.0602\u20131.2464) and 1.0556 (0.9937\u20131.1215), respectively. The corresponding values for the area under the plasma concentration\u2010time curve within a dosing interval (AUC\n                      <jats:sub>\u03c4,ss<\/jats:sub>\n                      ) were 1.0031 (0.9541\u20131.0545), 1.2264 (1.1383\u20131.3213) and 1.1638 (1.0958\u20131.2361) respectively. A 24\u2010h urinary glucose excretion (UGE\n                      <jats:sub>0\u201024h<\/jats:sub>\n                      ) induced by E was affected by coadministration of GM, with the GMR (90% CI) of 0.7834 (0.7307\u20130.8400). Serum glucose reduction was greatest with the E\u2009+\u2009GM, followed by GM, and then E.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      No clinically meaningful PK interaction of enavogliflozin, glimepiride and metformin was observed. Although a reduction in UGE\n                      <jats:sub>0\u201024h<\/jats:sub>\n                      was observed, an additive PD interaction was observed in serum glucose levels. The results suggest that enavogliflozin can be coadministered with glimepiride and metformin without requiring dose adjustments of either of these drugs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70861","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:10:58Z","timestamp":1792537858000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium\u2010glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4739-0604","authenticated-orcid":false,"given":"Kyungrin","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2141-2407","authenticated-orcid":false,"given":"Yoonjin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daye","family":"Jung","sequence":"additional","affiliation":[{"name":"Clinical Development Center Daewoong Pharmaceutical Co. Ltd  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1357-8386","authenticated-orcid":false,"given":"Jae Min","family":"Cho","sequence":"additional","affiliation":[{"name":"Clinical Development Center Daewoong Pharmaceutical Co. Ltd  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8273","authenticated-orcid":false,"given":"Joo\u2010Youn","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital  Seoul Republic of Korea"},{"name":"Department of Biomedical Sciences Seoul National University College of Medicine  Seoul Republic of Korea"},{"name":"Kidney Research Institute Seoul National University Medical Research Center  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-9194","authenticated-orcid":false,"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S009"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26180"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030268"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090865"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17121604"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030942"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15348"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15080"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15738"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi.1996.13.1.69"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi.1994.11.4.331"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi.1994.11.4.341"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010018\u201029351\u20104"},{"key":"e_1_2_11_15_1","unstructured":"Administration UFD.Highlights of prescribing information: AMARYL (glimepiride) tablets for oral use Initial U.S. Approval: 19951995.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020496s029lbl.pdf"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283559b22"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100270\u20106"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15632"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15613"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.472"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13659"},{"key":"e_1_2_11_22_1","first-page":"61","article-title":"Bioequivalence of Glucophage\u00ae (metformin) tablets from Europe and the United States tested in healthy volunteers","volume":"6","author":"Friedrich C","year":"2014","journal-title":"J Bioequiv Bioavailab"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70234"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70235"},{"key":"e_1_2_11_25_1","volume-title":"M12 drug interaction studies guidance for industry","author":"FDA","year":"2024"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010013\u20100128\u20108"},{"key":"e_1_2_11_27_1","unstructured":"Administration UFD.Highlights of prescribing information: GLUCOPHAGE (metformin hydrochloride) tablets for oral use inital U.S. Approval: 1995.1995https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020357s034 021202s018lbl.pdf"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902\u2010024\u201001727\u2010w"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70861","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70861","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:10:59Z","timestamp":1792537859000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":27,"alternative-id":["10.1002\/bcp.70861"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70861","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"bcp.70861"}}